For immediate release: May 05, 2004
VANCOUVER – Inex Pharmaceuticals Corporation ("INEX"; TSX:IEX) announced today that it will webcast its Annual General Meeting on Wednesday, May 12, 2004 at 1:30 PM. PST (4:30 PM EST).
About the webcast
The live or archived webcast can be accessed through the Company’s website at www.inexpharm.com.
About Inex Pharmaceuticals Corporation
INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer.
The Company’s lead product, Onco TCS, is a targeted chemotherapeutic combining the Company’s proprietary drug delivery technology with the off-patent anticancer drug vincristine. The Company announced in June 2003 that it had achieved positive results in a pivotal phase II/III clinical trial evaluating Onco TCS as a treatment for relapsed aggressive non-Hodgkin’s lymphoma. Onco TCS is also being evaluated in other phase II human clinical trials for lymphoma and other cancers.
INEX announced on March 15, 2004 that it had completed the New Drug Application (NDA) for Onco TCS seeking marketing approval from the United States Food and Drug Administration (FDA).
The Company announced in January 2004 that it had entered into a strategic partnership with Enzon Pharmaceuticals Inc. to develop and commercialize Onco TCS in North America.
INEX investor contact:
Ian Mortimer
Senior Director, Investor Relations
Inex Pharmaceuticals Corporation
Tel: 604.419.3200
Email: info@inexpharm.com
Website: www.inexpharm.com
INEX media contact:
Miriam Zitner
James Hoggan & Associates Inc.
Tel: 604.739.7500
Email: mzitner@hoggan.com
INEX’s common shares are traded on the Toronto Stock Exchange under the trading symbol “IEX”.
